HomeCompareZIOP vs JEPQ

ZIOP vs JEPQ: Dividend Comparison 2026

ZIOP yields 231.03% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZIOP wins by $281.95M in total portfolio value
10 years
ZIOP
ZIOP
● Live price
231.03%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281.99M
Annual income
$152,307,756.02
Full ZIOP calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — ZIOP vs JEPQ

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZIOPJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZIOP + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZIOP pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP
Annual income on $10K today (after 15% tax)
$19,637.29/yr
After 10yr DRIP, annual income (after tax)
$129,461,592.62/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, ZIOP beats the other by $129,459,762.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + JEPQ for your $10,000?

ZIOP: 50%JEPQ: 50%
100% JEPQ50/50100% ZIOP
Portfolio after 10yr
$141.02M
Annual income
$76,154,954.30/yr
Blended yield
54.00%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys
0
JEPQ buys
0
No recent congressional trades found for ZIOP or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZIOPJEPQ
Forward yield231.03%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$281.99M$44.8K
Annual income after 10y$152,307,756.02$2,152.59
Total dividends collected$267.75M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ZIOP vs JEPQ ($10,000, DRIP)

YearZIOP PortfolioZIOP Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$33,803$23,102.69$11,930$1,110.39+$21.9KZIOP
2$109,153$72,984.41$14,133$1,224.34+$95.0KZIOP
3$337,052$220,258.08$16,632$1,340.46+$320.4KZIOP
4$996,281$635,635.69$19,454$1,457.97+$976.8KZIOP
5$2,821,960$1,755,939.31$22,626$1,576.08+$2.80MZIOP
6$7,667,803$4,648,304.92$26,175$1,694.09+$7.64MZIOP
7$20,008,593$11,804,044.41$30,133$1,811.32+$19.98MZIOP
8$50,195,948$28,786,753.46$34,531$1,927.17+$50.16MZIOP
9$121,203,020$67,493,355.30$39,403$2,041.08+$121.16MZIOP
10$281,994,987$152,307,756.02$44,787$2,152.59+$281.95MZIOP

ZIOP vs JEPQ: Complete Analysis 2026

ZIOPStock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this ZIOP vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHDZIOP vs JEPIZIOP vs OZIOP vs KOZIOP vs MAINZIOP vs XYLDZIOP vs QYLDZIOP vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.